Eli Lilly’s existing 14-month evaluation agreement with Peptron, signed in October 2024, grants only non-exclusive rights for internal R&D on SmartDepot’s ultrasonic spray-dried microsphere platform for sustained-release peptide formulations. Lilly’s June 2025 exclusive licensing deal with Camurus for competing long-acting injectable technology has diverted attention, while no public filings or announcements confirm progression to a full commercial license. With the October 7, 2026 resolution date approaching and just months remaining, traders see limited catalysts for a binding agreement, reflected in the 79.5% “No” odds.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated$10,111 Vol.
$10,111 Vol.
Oct 7, 2026
$10,111 Vol.
$10,111 Vol.
Oct 7, 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s existing 14-month evaluation agreement with Peptron, signed in October 2024, grants only non-exclusive rights for internal R&D on SmartDepot’s ultrasonic spray-dried microsphere platform for sustained-release peptide formulations. Lilly’s June 2025 exclusive licensing deal with Camurus for competing long-acting injectable technology has diverted attention, while no public filings or announcements confirm progression to a full commercial license. With the October 7, 2026 resolution date approaching and just months remaining, traders see limited catalysts for a binding agreement, reflected in the 79.5% “No” odds.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Market Opened: May 5, 2026, 8:02 PM ET
Volume
$10,111End Date
Oct 7, 2026Market Opened
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s existing 14-month evaluation agreement with Peptron, signed in October 2024, grants only non-exclusive rights for internal R&D on SmartDepot’s ultrasonic spray-dried microsphere platform for sustained-release peptide formulations. Lilly’s June 2025 exclusive licensing deal with Camurus for competing long-acting injectable technology has diverted attention, while no public filings or announcements confirm progression to a full commercial license. With the October 7, 2026 resolution date approaching and just months remaining, traders see limited catalysts for a binding agreement, reflected in the 79.5% “No” odds.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volume
$10,111End Date
Oct 7, 2026Market Opened
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s existing 14-month evaluation agreement with Peptron, signed in October 2024, grants only non-exclusive rights for internal R&D on SmartDepot’s ultrasonic spray-dried microsphere platform for sustained-release peptide formulations. Lilly’s June 2025 exclusive licensing deal with Camurus for competing long-acting injectable technology has diverted attention, while no public filings or announcements confirm progression to a full commercial license. With the October 7, 2026 resolution date approaching and just months remaining, traders see limited catalysts for a binding agreement, reflected in the 79.5% “No” odds.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated

Beware of external links.
Beware of external links.
Frequently Asked Questions